Innate Immunotherapeutics is an Australian medical biotechnology company advancing the development of drugs that inhibit Focal Adhesion Kinase (FAK). The Company has two FAK inhibiting drug candidates which are being initially positioned for clinical development targeting pancreatic cancer, high grade serous ovarian cancer, and idiopathic pulmonary fibrosis.


To view Innate Immunotherapeutics Share Price, visit the ASX website here

Latest News
Annual Report

View our latest annual report
Email Alerts

Subscribe to our email alerts service.